Key takeawaysUCLA researchers have developed a CAR-NKT cell therapy that has shown to be more effective than current ...
Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...
Phase I clinical trials, using αGalCer-loaded DCs to target iNKT cells, have shown promise in treating some patients with cancer. As humans have a low frequency of iNKT cells, therapies that combine ...
Company’s lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells early in the inflammatory cascade to prevent cytokine release, cellular ...
Researchers at UCLA have developed a powerful new weapon in the battle against kidney cancer. Instead of relying on treatments tailored to each patient, this innovation uses specially engineered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback